Philippines in rush with other countries to buy experimental COVID-19 pills

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. (Merck & Co Inc/Handout via Reuters)

The U.S. Food and Drug Administration (FDA) last week authorised Merck’s antiviral COVID-19 pill for high-risk adult patients, a day after giving a broadergo-ahead to a similar but more effective treatment from Pfizer.

In the last week, Japan and India have also recommended approval of Merck’s experimental pill – which has already been approved in Britain, Denmark and the Philippines, among others while South Korea on Monday authorized Pfizer’s treatment for emergency use.

Merck has signed deals to sell about nine million courses of its treatment to governments around the world, but on Dec. 22France became the first country to publicly say it had cancelled its order following disappointing trial data. It hopes instead to receive Pfizer’s drug before the end of January.

In the European Union, both treatments are under review by the European Medicines Agency (EMA), though the regulator has said they can be used in adults ahead of any wider recommendation.

The following tables list countries that have expressed interest in Merck or Pfizer pills, sorted alphabetically:

Merck pill
COUNTRY VOLUME PRICE TIMING OF DELIVERY
Australia 300,000 doses
Belgium 10,000 doses
Canada 500,000 courses
Indonesia 600,000 – 1 million doses December 2021
Italy 50,000 courses
Japan 1.6 million courses $1.2 billion
Malaysia 150,000 courses
Philippines 300,000 courses P100-150 ($1.97-$2.96) per pill November 2021
South Korea 200,000 courses
Switzerland 8,640 doses January 2022 “at the latest”
Thailand 200,000 courses
UK 2.23 million courses Early 2022
United States 3.1 million courses $700 per course
Pfizer pill
COUNTRY VOLUME PRICE TIMING OF DELIVERY
Australia 500,000 courses https://bit.ly/3BTUQeL
Canada 1 million doses
Israel 100,000 courses
Italy 50,000 courses
South Korea 70,000 courses
UK 2.75 million courses Early 2022
United States 10 million courses $530 per course By end-2021

 

— Reporting by Ina Kreutz, Agnieszka Gosciak and Federica Urso;Editing by Milla Nissi and Barbara Lewis

Show comments